









Lutetium (177Lu) Vipivotide Tetraxetan (PLUVICTO) RPT Therapy Referral Form

Protocol Code UGUPLVT, Genitourinary Tumour Group BC Cancer Protocol for treatment of Metastatic Castration Resistant Prostate Cancer using Lutetium (177Lu) Vipivotide Tetraxetan (PLUVICTO)

REFERRAL DATE:

Z	V	ı	F	I		n	9	•	N	П	ı	S	т	Ŧ	3	Е	C	3	Ö	N	Л	P	Т	F	Ī	F	П	1	n	N	г	П	н	Ī.	S	=(n	R	2	V

Email completed referral to: pluvictoreferrals@bccancer.bc.ca

PATIENT INFORMATION:

LAST NAME (PLEASE PRINT) FIRST NAME (PLEASE PRINT) PERSONAL HEALTH NUMBER

HOME PHONE CELL PHONE BC CANCER MRN (OR ID)

DATE OF BIRTH (DAY/MONTH/YEAR) PATIENT EMAIL

HOME ADDRESS CITY **PROVINCE**

PREFERRED METHOD OF CONTACT (PLEASE CHECK) POSTAL CODE

EMAIL HOME PHONE CELL PHONE

REFERRING PHYSICIAN'S INFORMATION:

REFERRING PHYSICIAN'S LAST NAME REFERRING PHYSICIAN'S FIRST NAME MSP NUMBER

PHYSICIAN SIGNATURE (REQUIRED) REFERRING PHYSICIAN'S OFFICE PHONE

ADDITIONAL INFORMATION:

HAD PRIOR RADIONUCLIDE THERAPY FOR PROSTATE CANCER (IE RADIUM 223 OR PLUVICTO)? - <i>CHECK YES OR NO</i>	YES	NO
IF YES, DATE:		
PSMA SCAN WITHIN 6 MONTHS? - CHECK YES OR NO	YES	NO
CAP APPROVAL COMPLETE (MANDATORY REQUIREMENT)		
DOES PATIENT REQUIRE AN INTERPRETER? - CHECK YES OR NO IF YES, LANGUAGE:	YES	NO
S PATIENT AMBULATORY WITHOUT ASSISTIVE AIDS (NO WHEELCHAIR OR WALKER)? - CHECK YES OR NO	YES	NO